Why is OncuraKit relevant for ovarian cancer detection?

Ovarian cancer is diagnosed at Stage III or IV in approximately 75% of cases because it causes few or no symptoms in early stages and has no standard population screening test. The traditional CA-125 blood test has poor specificity for early ovarian cancer detection (many benign conditions elevate CA-125). Transvaginal ultrasound is also insufficiently sensitive for early detection. The USPSTF currently recommends against routine ovarian cancer screening due to these limitations. OncuraKit provides a non-invasive, urine-based alternative that measures miR-21, miR-375, and miR-141 — all of which are overexpressed in ovarian cancer. For women at elevated risk (BRCA1/2 carriers, family history) or those with vague pelvic symptoms, OncuraKit offers an additional screening dimension currently unavailable through conventional tools.